Akums Drugs held a conference call to discuss Q4 and FY26 results, reporting a 9.7% YoY revenue growth to ₹1,158 crore and a 61.6% YoY EBITDA jump to ₹152 crore.
Management provided a strategic update, highlighting a strong CDMO performance with 13.4% YoY growth and the turnaround of the trade generics segment to EBITDA positive.
Key forward-looking initiatives include the ramp-up of a new injectables facility, the execution of a $25 million Zambia supply contract, and the planned commencement of a €35 million annual European contract from FY28.
The Board recommended a final dividend of ₹1 and a special dividend of ₹2 per equity share for FY26, while the company maintains a strong cash position of ₹1,682 crore.